203 related articles for article (PubMed ID: 17721109)
1. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
[TBL] [Abstract][Full Text] [Related]
2. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
3. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
[TBL] [Abstract][Full Text] [Related]
4. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores.
Walmsley SL; Cotte L; Rusconi S; Ward DJ; Hicks CB; Meier U; Valdez H; Boucher CA
AIDS; 2007 Oct; 21(16):2245-8. PubMed ID: 18090054
[TBL] [Abstract][Full Text] [Related]
5. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M; Staszweski S; Clotet B; Arribas JR; Blaxhult A; Carosi G; Dejesus E; Di Perri G; Estrada V; Fisher M; Kovacs C; Kulasegaram R; Lazzarin A; Marriott D; Muñoz L; Reynes J; Shalit P; Slim J; Tsoukas C; Vaccaro A; Vera J
HIV Clin Trials; 2006; 7(2):86-96. PubMed ID: 16798623
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.
Sozio F; Polilli E; D'Annunzio M; Falconi L; Di Masi F; Tontodonati M; Cosentino L; Consorte A; Di Giammartino D; Parruti G
Infez Med; 2009 Dec; 17(4):228-35. PubMed ID: 20046103
[TBL] [Abstract][Full Text] [Related]
7. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.
Feiterna-Sperling C; Walter H; Wahn V; Kleinkauf N
Eur J Med Res; 2009 Jan; 14(1):44-6. PubMed ID: 19258211
[TBL] [Abstract][Full Text] [Related]
8. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.
Ruxrungtham K; Boyd M; Bellibas SE; Zhang X; Dorr A; Kolis S; Kinchelow T; Buss N; Patel IH
J Clin Pharmacol; 2004 Jul; 44(7):793-803. PubMed ID: 15199084
[TBL] [Abstract][Full Text] [Related]
9. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM
Antimicrob Agents Chemother; 2011 Jul; 55(7):3613-5. PubMed ID: 21576452
[TBL] [Abstract][Full Text] [Related]
10. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
12. Tipranavir: new drug. HIV protease inhibitor. A last resort.
Prescrire Int; 2006 Dec; 15(86):217-9. PubMed ID: 17167925
[TBL] [Abstract][Full Text] [Related]
13. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
[TBL] [Abstract][Full Text] [Related]
14. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Arribas JR
Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
[TBL] [Abstract][Full Text] [Related]
15. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Berhan A; Berhan Y
PLoS One; 2013; 8(4):e60814. PubMed ID: 23593314
[TBL] [Abstract][Full Text] [Related]
16. [Desensitization to tipranavir caused by toxicodermia].
Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
[No Abstract] [Full Text] [Related]
17. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
Boyd MA; Dixit NM; Siangphoe U; Buss NE; Salgo MP; Lange JM; Phanuphak P; Cooper DA; Perelson AS; Ruxrungtham K
J Infect Dis; 2006 Nov; 194(9):1319-22. PubMed ID: 17041859
[TBL] [Abstract][Full Text] [Related]
18. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
Edmunds-Ogbuokiri T
HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
[No Abstract] [Full Text] [Related]
19. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
[TBL] [Abstract][Full Text] [Related]
20. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
